Trial Outcomes & Findings for Trigger Point Injections in Anterior Cervical Surgery (NCT NCT04640896)
NCT ID: NCT04640896
Last Updated: 2026-08-13
Results Overview
Milligrams morphine equivalents (MME)
COMPLETED
PHASE4
60 participants
6 hours after intervention
2026-08-13
Participant Flow
Participant milestones
| Measure |
Lidocaine Skin Wheal
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Overall Study
STARTED
|
19
|
23
|
18
|
|
Overall Study
COMPLETED
|
19
|
23
|
18
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Trigger Point Injections in Anterior Cervical Surgery
Baseline characteristics by cohort
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Total
n=60 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=2 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
16 Participants
n=1 Participants
|
18 Participants
n=1 Participants
|
10 Participants
n=1 Participants
|
44 Participants
n=2 Participants
|
|
Age, Categorical
>=65 years
|
3 Participants
n=1 Participants
|
5 Participants
n=1 Participants
|
8 Participants
n=1 Participants
|
16 Participants
n=2 Participants
|
|
Sex: Female, Male
Female
|
12 Participants
n=1 Participants
|
7 Participants
n=1 Participants
|
8 Participants
n=1 Participants
|
27 Participants
n=2 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=1 Participants
|
16 Participants
n=1 Participants
|
10 Participants
n=1 Participants
|
33 Participants
n=2 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=2 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
1 Participants
n=1 Participants
|
2 Participants
n=2 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=2 Participants
|
|
Race (NIH/OMB)
Black or African American
|
7 Participants
n=1 Participants
|
7 Participants
n=1 Participants
|
6 Participants
n=1 Participants
|
20 Participants
n=2 Participants
|
|
Race (NIH/OMB)
White
|
11 Participants
n=1 Participants
|
16 Participants
n=1 Participants
|
11 Participants
n=1 Participants
|
38 Participants
n=2 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=2 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=2 Participants
|
PRIMARY outcome
Timeframe: 6 hours after interventionMilligrams morphine equivalents (MME)
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Opioid Consumption in the First 6 Hour Period After Intervention (Trigger Point Injection/Sham)
|
17.7 MME
Interval 0.0 to 60.0
|
15.9 MME
Interval 0.0 to 49.5
|
18.3 MME
Interval 0.0 to 45.0
|
PRIMARY outcome
Timeframe: 12 hours after interventionMilligrams morphine equivalents (MME)
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Opioid Consumption in the First 12 Hour Period After Intervention (Trigger Point Injection/Sham)
|
10.3 MME
Interval 0.0 to 37.5
|
7.8 MME
Interval 0.0 to 30.0
|
5.7 MME
Interval 0.0 to 19.5
|
PRIMARY outcome
Timeframe: 24 hours after interventionMilligrams morphine equivalents
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Opioid Consumption in the First 24 Hour Period After Intervention (Trigger Point Injection/Sham)
|
10.9 MME
Interval 0.0 to 42.0
|
12.5 MME
Interval 0.0 to 45.0
|
12.8 MME
Interval 0.0 to 45.0
|
SECONDARY outcome
Timeframe: 6 hours after interventionPain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain.
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Pain Score at 6 Hours After Intervention (Trigger Point Injection/Sham).
|
3.8 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 8.0
|
5.3 Numerical pain score 1-10 (10 is worse)
Interval 1.0 to 10.0
|
5.9 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
|
SECONDARY outcome
Timeframe: 12 hours after interventionPain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain.
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Pain Score at 12 Hours After Intervention (Trigger Point Injection/Sham)
|
3.8 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 8.0
|
4.9 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
|
5.5 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
|
SECONDARY outcome
Timeframe: 24 hours after interventionPain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain.
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Pain Score at 24 Hours After Intervention (Trigger Point Injection/Sham)
|
3.9 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 8.0
|
4.3 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
|
4.1 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
|
SECONDARY outcome
Timeframe: Through hospital discharge, an average of 2 daysMeasured in days and hours
Outcome measures
| Measure |
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.
However, this skin wheal is not considered a trigger point injection.
|
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
|
|---|---|---|---|
|
Post-operative Length of Stay
|
1.05 Days
Interval 0.0 to 4.0
|
1.43 Days
Interval 0.0 to 12.0
|
1.22 Days
Interval 0.0 to 6.0
|
Adverse Events
Lidocaine Skin Wheal
Trigger Point Injection With Normal Saline
Trigger Point Injection With Bupivacaine
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place